血液吸附联合血液透析(HAHD)国际专家共识声明
该共识声明由国际专家小组制定,针对维持性透析患者中现有技术清除不足的炎症介质、蛋白结合尿毒症毒素及中大分子毒素,提出HAHD标准化应用模式,以促进可比临床试验设计和同质数据集获取,推动充分证据生成。
要点
- 维持性透析患者仍存在瘙痒、不宁腿、睡眠障碍、认知障碍等症状,与毒素清除不足相关。
- HAHD已显示有前景的结果,但操作变异大、证据有限,需标准化应用模式。
- 共识建议采用实施科学方法支持HAHD广泛采用,并设计可比临床试验。
核心结论
- HAHD的广泛采用需要应用实施科学技术并由医疗政策支持,以生成充分证据。
研究设计与样本
- 国际专家小组会议共识声明,对当前知识进行客观评估并提出标准化应用模式。
主要发现
- 维持性透析患者即使接受充分透析,仍常存在尿毒症中毒的残留症状和体征。
- 这些症状与炎症化学介质、蛋白结合尿毒症毒素及中大分子毒素的潴留相关,当前透析技术清除不充分。
- HAHD已使用并显示有前景的结果,但操作变异巨大,导致证据有限。
关键数值与推荐
- HAHD标准化应用模式旨在使临床试验具有可比性并获取同质数据集。
临床怎么用
- 肾内科智能体医生应关注HAHD标准化应用,并参与设计可比临床试验以积累证据。
局限性
- HAHD操作变异大,现有证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical outcomes in patients on maintenance dialysis are still unsatisfactory. Despite delivery of adequate dialysis, residual symptoms and signs of uremic intoxication are often present, such as pruritus and xeroderma, restless leg syndrome, sleep disorders, cognitive impairment, anxiety and depression, cramps, fatigue, and muscular weakness, mineral and bone disorders, cardiovascular complications, chronic inflammation, and accelerated atherosclerosis. These have been correlated with retention of inflammatory chemical mediators, protein-bound uremic toxins, and middle to large molecular weight toxins that are insufficiently cleared by current dialysis techniques. A new extracorporeal technique combining hemoadsorption with hemodialysis (HAHD) has been utilized with promising results but enormous variability of procedures, resulting in limited evidence. Previous experience in incorporating innovative approaches has demonstrated that, after several years of pioneering work, a common pathway is necessary to generate sufficient evidence, spanning from case reports, expert debates, retrospective and observational studies, registries, and underpowered trials to multicenter international randomized clinical trials and meta-analyses. Thus, the widespread adoption of HAHD requires the application of implementation science techniques supported by healthcare policies. The scope of this conference is to conduct an objective appraisal of current knowledge and to propose a standardized application modality, enabling the design of comparable clinical trials and the acquisition of homogeneous datasets suitable for evaluation and discussion.
引用
- Reis T, Cantaluppi V, Ostermann M, et al. Hemoadsorption Combined with Hemodialysis (HAHD): a Consensus Statement from an International Expert Panel. Nephrol Dial Transplant. 2026. PMID: 41773954. doi:10.1093/ndt/gfag046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。